Cerebrolysin
Also known as: FPF 1070
Cerebrolysin is a catalog-expanded peptide entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, local_seed, seed corpus peptides. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Porcine-derived peptide preparation. Approved in many European and Asian countries for stroke, TBI, and dementia. Dose is in mL of a standard formulation rather than mg.
Typical protocol: 10-20 daily infusions followed by several weeks off.
Off-cycle: 8 weeks
IM or slow IV infusion — not for subcutaneous use.
Contraindications
- • Severe renal failure
- • Status epilepticus
- • Hypersensitivity to porcine proteins
Common side effects
- • Injection site reactions
- • Sweating
- • Dizziness
- • Agitation (dose-dependent)
Serious risks
- • Seizure risk in patients with epilepsy
- • Allergic reactions (porcine-derived)
Drug interactions
- • Additive effects with MAOIs and antidepressants
Pregnancy / breastfeeding
Not recommended during pregnancy
- Not subcutaneous — must be given IM or as slow IV infusion
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.